Table 3 Antituberculosis drugs susceptibility testing in Reunion Island patients with tuberculosis
From: Epidemiology of tuberculosis and susceptibility to antituberculosis drugs in Reunion Island
n = 216 | |
|---|---|
Anti tuberculosis drugs susceptibility | 185 (85.6) |
Anti tuberculosis drugs resistance | 31 (14.4) |
Rifampicin | 4 (1.9) |
Phenotypic resistance (n = 213) | 4 (1.9) |
Genotypic resistance: rpoB gene mutation (n = 113) | 2 (1.8)* |
Isoniazid | 12 (5.6) |
Phenotypic resistance (n = 213) (n = 91) | 12 (5.6) |
Genotypic resistance (n = 113): | 7 (7.7)* |
katG mutation | 4 (4.4) |
inhA mutation | 3 (3.3) |
Pyrazinamide phenotypic resistance | 14 (6.5) |
Ethambutol phenotypic resistance | 1 (0.5) |
Streptomycin phenotypic resistance | 11 (5.1) |
Isoniazid monoresistance | 4 (1.8) |
MDR tuberculosis | 3 (1.4) |
XDR tuberculosis | 0 (0) |
Primary resistance | 29 (13.2) |
Secondary resistance | 2 (0.9) |